In conclusion, the potential beneficial effects of BMP9 ligand therapy for treating PAH are likely limited and overshadowed by the potent adverse effects that we identified and further understanding of BMP9s’ mechanisms of action in regulating angiogenesis is required. Here, GDF2 is linked to pulmonary arterial hypertension.